DOTS strategy

DOTS strategy
"Photo Credit: The photo of Mycobacterium tuberculosis was obtained from the Cen · Public domain · source
Name	DOTS strategy
Introduced	1990s
Origin	World Health Organization
Type	Public health strategy
Purpose	Tuberculosis control

DOTS strategy is a standardized approach to tuberculosis control introduced by the World Health Organization in the early 1990s. It was formulated to strengthen case detection and treatment adherence through a structured package of interventions associated with the WHO Global Tuberculosis Programme, the International Union Against Tuberculosis and Lung Disease and national tuberculosis programs in countries such as India, China, and South Africa. The strategy was promoted alongside international initiatives such as the Millennium Development Goals and later aligned with the Sustainable Development Goals to reduce the burden of tuberculosis globally.

Background and history

The DOTS package emerged amid rising concern about multidrug-resistant tuberculosis during the late 1970s and 1980s that involved stakeholders including the Centers for Disease Control and Prevention and the Royal Society of Tropical Medicine and Hygiene. Early models of directly observed therapy were trialed in settings like New York City and Peru where public health crises intersected with socioeconomic disruption. The formal WHO endorsement followed reviews by the World Health Assembly and technical guidance from the Global Fund to Fight AIDS, Tuberculosis and Malaria and was integrated into national policies in countries guided by policy instruments such as the Alma-Ata Declaration principles of primary health care and health systems strengthening advocated by the World Bank.

Core components and implementation

DOTS comprises five operational elements that shaped national programs coordinated by ministries such as the Ministry of Health (India) and institutions like the National TB Program (South Africa). Programs emphasized standardized diagnosis using sputum smear microscopy developed in laboratories aligned with quality assurance networks including the European Centre for Disease Prevention and Control protocols and specimen transport systems established with partners such as Médecins Sans Frontières and the Bill & Melinda Gates Foundation. Treatment regimens relied on fixed-duration short-course chemotherapy with first-line drugs recommended by the WHO Expert Committee on Tuberculosis and supervised delivery models influenced by community health worker cadres from initiatives in Ethiopia and China. Recording and reporting were standardized through registers and surveillance linked to national health information systems like those promoted by the Global Health Observatory; program financing and advocacy often involved multilateral donors such as the World Bank and bilateral agencies including USAID.

Global adoption and program outcomes

By the early 2000s, countries across regions—Southeast Asia Regional Office (WHO) countries including Bangladesh, Indonesia, and Thailand; African Region (WHO) countries such as Botswana and Zimbabwe; and European Region (WHO) states like Romania—had adopted DOTS components within national strategies. Evaluations by the WHO Global TB Programme and research published by investigators affiliated with institutions like the London School of Hygiene & Tropical Medicine and Imperial College London reported improvements in case detection rates and treatment success in many implementation settings. Notable program results were documented in large-scale rollouts such as the Revised National Tuberculosis Control Programme (India) scale-up and community-based trials in Peru, which demonstrated reductions in default rates and increases in cure rates that informed subsequent guidelines and the work of the Stop TB Partnership.

Challenges and criticisms

Critiques emerged from academic centers including Harvard T.H. Chan School of Public Health and activist organizations like Treatment Action Campaign focusing on limitations in addressing drug-resistant tuberculosis and barriers faced by marginalized populations in urban centers such as Johannesburg and Mumbai. Operational challenges included laboratory capacity gaps highlighted in reports by the Centers for Disease Control and Prevention and supply-chain disruptions noted by the Global Drug Facility, which affected access to quality-assured medicines. There were debates about the emphasis on sputum smear microscopy versus newer diagnostics developed by entities such as Cepheid and endorsed later by the World Health Organization for molecular testing, as well as concerns raised in legal and human rights forums including cases referenced in the African Commission on Human and Peoples' Rights about coercion associated with directly observed therapy. Economic analyses from the World Bank and health policy scholars questioned sustainability of financing when external funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria fluctuated.

Impact on tuberculosis control and legacy

Despite criticisms, DOTS influenced global standards and capacity building within surveillance networks such as the Global Tuberculosis Report framework and informed successor strategies promoted by the World Health Organization including the End TB Strategy. The approach catalyzed investments in laboratory systems at institutions modeled on centers like the KNCV Tuberculosis Foundation and spurred the development of community health worker programs in settings exemplified by Brazil’s primary care reforms and pilot projects in Uganda. DOTS’ emphasis on standardized recording, supervised treatment, and political commitment left a durable imprint on national tuberculosis programs, shaping policy dialogues in forums such as the World Health Assembly and partnerships like the Stop TB Partnership while informing contemporary efforts to integrate novel diagnostics, shorter regimens, and multisectoral responses to control tuberculosis worldwide.

Category:Tuberculosis